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CObjective: There is a paucity of evidence about insurance status and
the likelihood of receiving medical services in Latin America. The
objective of this analysis was to examine the association between
insurance status and pharmacologic treatment for depression.
Methods: Patients referred to a memory clinic of a public hospital in
Buenos Aires, Argentina, and identified with any of four types of
depression (subsyndromal, dysthymia, major, and due to dementia)
were included. Age, years of education, insurance status, Beck De-
pression Inventory score, and number of comorbidities were consid-
ered. Associations between these factors and not receiving pharma-
cologic treatment for depression were examined with logistic
regression. Use of prescription neuroleptics, hypnotics, and anticho-
linesterase inhibitors was also explored. Results: Out of 100 pa-
tients, 92 with insurance status data were used. Sixty-one patients
(66%) had formal insurance and 31 patients (34%) lacked insurance.
Twenty-seven (44%) insured patients and 23 (74%) uninsured pa- O
hav
Cogn
al So
oi:10.1016/j.jval.2011.05.014ients did not receive antidepressants (P  0.001). Controlling for
ther factors, uninsured patients had 7.12 higher odds of not receiv-
ng treatment compared to insured patients (95% confidence interval
.88–28.86). Older patients and those with more comorbidities had
igher odds of not receiving treatment. More educated patients,
hose with higher Beck Depression Inventory score, and those with-
ut subsyndromal depression had lower odds of not receiving treat-
ent. None of those associations were statistically significant.
onclusions: These results suggest a potential negative effect of the
ack of formal insurance regarding pharmacologic treatment for de-
ression. These findings should be confirmed with larger samples,
nd for other diseases.
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utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Depression represents a concern to public health because it is
one of the most burdensome diseases [1] and it also exacts a
considerable economic [2] and humanistic burden [3]. Pharma-
cologic and othermental health treatment rates remain low and
variable in international comparisons [4]. Out-of-pocket costs
[4] and lack of insurance [5] have been identified as factors as-
sociated with lower treatment rates. A Latin American city in-
volved in an international study ranked among the lowest in
terms of antidepressant therapy rates and was among the first
citing financial barriers as a reason for not receiving treatment
[4]. More than 40% of Argentineans rely on public infrastructure
for their health care [6]. Although during the past decade federal
coverage of essential medicines has been developed [7], the
scope of the plan is limited.
Evidence supports a link between lack of insurance (or reduced
coverage) and reduced access to pharmacologic or nonpharmaco-
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ublished by Elsevier Inc.logic medical treatment, as well as with impaired medication per-
sistence. Latin American data coincide with these findings. An
analysis of Mexican elderly patients [8] showed that presence of
health insurance was associated with improved access tomedica-
tions. Lack of insurance was identified as a risk factor for cata-
strophic health expenditures in Mexico [9] and Colombian data
support the link between no insurance or lower quality insurance
and reduced human immunodeficiency virus/autoimmune defi-
ciency syndrome medication adherence [10]. To our knowledge
few investigations addressed care for depression in low income,
uninsured individuals in Latin America [11–14].
The primary objective of this research was to assess the as-
sociation between antidepressant pharmacotherapy and insur-
ance status, controlling for demographic and clinical factors.
The secondary objective was to explore the associations be-
tween insurance status and other factors and treatment with
prescription neuroleptics, hypnotics, and anticholinesterase in-
hibitors.
e no conflicts of interest with regard to the content of this
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Patient population
The study population consisted in patients evaluated at the Mem-
ory Clinic at Zubizarreta Hospital in Buenos Aires, Argentina. A
clinical database with the data collected as part of the initial visit
of the patient was used [15–16].
Thiswas a cross-sectional study. Patients referred for impaired
memory and depressive symptoms and assessed in the period
2005 to 2009 were included. All of them were assessed using a
semistructured neuropsychiatric interview (administered by spe-
cialized psychiatrists and neurologists). Depressive syndromes
were categorized into different diagnoses according to the DSM IV
[17] and ICD-10 criteria [18] using SCAN 2.1: Schedules [19] for
clinical assessment in neuropsychiatry.
Four types of depression were confirmed. These were: 1) sub-
syndromal depression (diagnosed when patients experience de-
pressive symptoms but do not meet standard diagnostic criteria);
2) dysthymia (a syndrome of depression of mild or moderate se-
verity that lasts at least 2 years); 3) major depression; and 4) de-
pression associated with dementia (Alzheimer disease and vascu-
lar and mixed dementia).
Patients were included if they had a minimum age of 55 years
and were younger than 80 years old, if they presented depressive
symptoms due to psychiatric causes or related with dementia
(with clinical dementia rating scale [CDR] [20] score of 1) and if they
had a Hamilton Depression Scale [21] score greater than 9 points.
Exclusion criteria covered: 1) drug or alcohol abuse; 2) presence of
neurologic diseases (except dementia); 3) dementia andCDR score of
2 or CDR score of 3; and 4) schizophrenia or schizoaffective disorder.
Written informed consent was obtained from each subject af-
ter they had been given a full explanation of the study. The re-
search was performed in accordance with the International Con-
ference on Harmonisation Good Clinical Practice guidelines [22],
the latest revision of the 1964 Helsinki Declaration [23], and the
Buenos Aires Government Health Authorities.
Study variables
Patients’ demographic data included age, sex, education level, and
income. Health insurance statuswas recorded as: PAMI (Medicare-
like system for retired persons aged 65 years and special groups),
sickness fund (insurance linked to employment), and privately
paid insurance or public system.
Patient depression severity was assessed with the Beck Depres-
sion Inventory (BDI), a questionnaire with a 0 to 63 total score [24].
Higher scores indicatemore depressive symptoms. TheMini-Mental
Scale Examination (MMSE) for cognitive impairment was used (0 to
30 score, with lower scores indicating higher cognitive impairment)
[25]. Patient comorbiditieswere recordedand includedhypertension,
diabetes, cardiovascular and cerebrovascular disease, dyslipidemia,
tobacco use and alcohol abuse, hypo- and hyperthyroidism, en-
cephalo cranial traumatism, epilepsy, Parkinson’s disease, and other
concomitant diseases. Assessed medications included antidepres-
sants (trycyclics and serotonin-reuptake inhibitors), anticholinester-
ase inhibitors, neuroleptics, and hypnotics.
Statistical analysis
All analyses were performed with R version 2.11.1 [26].
Patients were aggregated in two groups. Group 1 were those
with PAMI, sickness-fund, or private insurance and group 2 were
those relying on public services (labelled as uninsured due to the
lack of formal insurance services). Depression diagnosis was col-
lapsed into two groups: subsindromal depression and all other
diagnoses. Bivariable analysis usedWilcoxon tests for continuous
variables and Pearson’s chi-square tests for categorical variables.Primary multivariable analyses used as outcome not being pre-
scribed an antidepressant. Independent variables included insur-
ance status, age in years, education in years, depression diagnosis,
total BDI, and count of comorbidities. Models were repeated with
use of neuroleptics and hypnotics. A separate model was used for
anticholinesterate inhibitors (MMSE was included as independent
variable while BDI and depression diagnosis were dropped).
Results
One hundred patients were initially included in the study and 92
were retained due to missing insurance data. Patients not insured
were younger (median 59 vs. 70 years, P 0.001, mean 70.3 vs. 60.3),
hich is explained by the proportion of elderly insured patients. A
igher proportion of uninsured patients had subsyndromal depres-
ion (26% vs. 21%) and major depression (39% vs. 23%) (Table 1, in
upplemental Material found at: doi:10.1016/j.jval.2011.05.014).
A higher proportion of uninsured patients were not receiving
ntidepressants compared to insured patients (74% vs. 44%; P 
0.006). The proportion of patients not treated with anticholines-
terase inhibitors was similarly high among uninsured and insured
(92% vs. 94%; P  0.76). Eighty-one percent of uninsured patients
and 89% of insured patients were not receiving neuroleptics,
whereas 45% of uninsured patients and 34% of insured patients
were not receiving hypnotics.
A logistic regression model indicated that patients without in-
surance had 7.12 (95% confidence interval 1.88–26.86) higher odds
of not being prescribed an antidepressant compared to patients
with insurance (Table 2 in Supplemental Material found at: doi:
10.1016/j.jval.2011.05.014). No other point estimate reached statis-
tical significance. Increasing age andmore comorbidities were as-
sociated with higher odds of not receiving treatment whereas
more years of schooling, diagnosis other than subsyndromal de-
pression, and higher BDI were associated with lower odds of not
receiving treatment.
No health care insurancewas also associatedwith higher odds of
not being prescribed neuroleptics or hypnotics and with lower odds
of being prescribed anticholinesterase inhibitors, although the re-
sults were not statistically significant. Older agewas associatedwith
higher odds of not being prescribed hypnotics and lower odds of not
being prescribed anticholinesterase inhibitors. More years of educa-
tion were associated with lower odds of not being prescribed neuro-
leptics, hypnotics or anticholinesterase inhibitors (and it was the
onlystatistically significantfinding for thisendpoint).HigherBDIwas
associatedwith loweroddsofnot receivingneurolepticsorhipnotics.
A higher MMSE score was associated with lower odds of being pre-
scribed an anticholinesterase inhibitor.
Conclusions
Theassociationsbetween insurance statusandpharmacologic treat-
ment for depression in a clinic in Buenos Aireswere investigated. To
our knowledge, this is the one of the first reports about this topic in
South America. Previously, a study in Botucatu, Brazil [14], showed
thatpatients earning less than theminimumwagehadfive times the
odds of not receiving antidepressants compared to people earning
more than four times the minimum wage, even though essential
medicineswere in principle accessible to all socioeconomic strata. In
a multivariable model that accounted for demographic and clinical
factors uninsured patients had 7.12 higher odds of not receiving an-
tidepressant therapy, and the resultwas statistically significant. This
association was more important than the lower odds of receiving
treatment resulting from varying patient age from 59 to 74 years or
from the effect of being a subsindromal patient compared to any
other diagnosis (Fig. 1 in Supplemental Material found at: doi:
10.1016/j.jval.2011.05.014). The mean annual treatment rate for chil-
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proximately half the rate of insured children [5]. The relative
treatment proportions reported in this study are of similar magni-
tude. Although comparability is impaired by different endpoints and
settings, this odds ratio of 7.12 is similar to the odds ratio for report-
ing cost-related non adherence for uninsured patients [27] and lower
than the odds in the city of Botucatu [14]. Even if not statistically
significant, other associations had the expected direction. Older pa-
tients and those with more comorbidities had higher odds of not
receiving antidepressant treatment, which may be due to the com-
plexity of dealing with several conditions. Low treatment rates for
olderpatientshavebeen reported inLatinAmerica [28]. Patientswith
a higher BDI (more severe depression) had lower odds of not being
treated and patients with subsindromal depression had higher odds
of not being treated. More educated patients had lower odds of not
being treated. Thismaybea related tohigher likelihoodof insurance,
higher income, or more health-oriented behavior. This study had
some limitations. Sample sizeswere small but in contrast to a bigger
sampleof a single subsystem, this cohorthadavarietyof exposure to
different insurance status. Selection bias was present. Representa-
tiveness of the city of Buenos Aires or beyondmay be in doubt even
for the studied age group. It was not possible to estimate the same
relationships regarding nonpharmacologic treatment for depres-
sion. Confounding bias may have affected the findings. Some of the
differences may be due to observed or unobserved patient imbal-
ances; however, it is unlikely that unobserved confounders would
changesuchastrong relationshipbetween lackof insuranceand lack
ofantidepressant treatment. Finally, limitationsarise fromthecross-
sectional design. Depression history was not assessed. In the ex-
treme, if all uninsured cases were detected at the clinic and the in-
sured depressive cases were already diagnosed, higher treatment
rates may be explained by the higher depression diagnosis rate for
insured patients. This may dilute part of the association but it is
unlikely thatall of theassociationobservedwouldbedue to this.This
was probably not the first interactionwith the health care system for
the uninsured patients in this study, because these patients were
referred to the clinic. Therewere also some imbalances in the type of
depression but these seem to be in a direction that would favour
more treatment in the uninsured group, because a higher proportion
of patients hadmajor depression, although this was balancedwith a
higher proportion of insured patientswith dysthymia.Measurement
bias leading to misclassification may have occurred for medication
use if patients reported no use ofmedication but they dropped out of
current treatment or were not adherent to it. It is unlikely that such
bias would greatly affect the main finding, given its numerical
strength.
Interventions to enhance access and improve outcomes for pa-
tients with depression can succeed. A primary care program de-
signed for low-income women in Chile showed its effectiveness
and efficiency [11–12]. In the past 20 years, Brazil hasmade impor-
tant progress toward ensuring appropriate mental health care,
including enhanced access to essential psychotropic medication
[29]. There is a need to monitor such policies to evaluate their
effects and detect remaining access gaps.
Lack of insurance with comprehensive pharmaceutical coverage
was associated with much higher odds of not receiving pharmaco-
logic treatment for depression in a cohort in Buenos Aires. Future
studies should explore this relationship in larger samples with
broader geographical scope, and into other areas of medical care.
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